Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Islets of Langerhans

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Islets of Langerhans. Displaying page 1 of 1.
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005806-38 Sponsor Protocol Number: NO21884 Start Date*: 2009-10-23
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with a...
    Medical condition: PIb: solid malignancy that is metastatic or unresectable PII: C 1: Advanced metastatic renal cell carcinoma C 2: Advanced low- to intermediate grade metastatic or unresectable locoregional pancre...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050076 Metastatic renal carcinoma LLT
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052399 Neuroendocrine tumour LLT
    9.1 10026664 Malignant pancreatic islet neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003936-21 Sponsor Protocol Number: TD-212-2308 Start Date*: 2015-09-14
    Sponsor Name:Hôpital de Jolimont
    Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE...
    Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019424-31 Sponsor Protocol Number: REP0110 Start Date*: 2010-08-31
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following islet transplantation in patients with type 1 diabetes mellitus
    Medical condition: intrahepatic islet transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10058846 Pancreas islet cell transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000425-45 Sponsor Protocol Number: Start Date*: 2012-07-03
    Sponsor Name:
    Full Title: Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.
    Medical condition: Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055008 Gastric sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000888-41 Sponsor Protocol Number: MetNET1trial Start Date*: 2014-06-05
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori
    Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono...
    Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-006201-10 Sponsor Protocol Number: REP0211 Start Date*: 2012-08-13
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation
    Medical condition: Pancreatic islet transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10058846 Pancreas islet cell transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004069-14 Sponsor Protocol Number: PRODIGE31 Start Date*: 2015-01-22
    Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD)
    Full Title: A european, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrin...
    Medical condition: Non-resectable duodeno-pancreatic neuroendocrine tumours after first line treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005919-30 Sponsor Protocol Number: AK_NEN_DOTA-FDG_21 Start Date*: 2022-09-21
    Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet
    Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms
    Medical condition: Neuroendocrine neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085846 Duodenal neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085958 Small intestine neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004022-87 Sponsor Protocol Number: A6181111 Start Date*: 2007-04-05
    Sponsor Name:Pfizer Inc. [...]
    1. Pfizer Inc.
    2. Pfizer bv CR
    3. Pfizer bv RA
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS
    Medical condition: Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 Pancreatic neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000726-66 Sponsor Protocol Number: GETNE1206 Start Date*: 2014-10-08
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by ...
    Medical condition: advanced progressive pNETs
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) ES (Completed) DK (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-005028-13 Sponsor Protocol Number: MK-6482-015 Start Date*: 2021-07-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendoc...
    Medical condition: Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumor or von Hippel-Lindau (VHL) Disease-Associated Tumors or Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors with HIF...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10034876 Pheochromocytoma LLT
    20.0 100000004864 10073860 Paraganglioma LLT
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10047716 Von Hippel-Lindau disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:23:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA